Our investment strategy
We invest in next-generation life science companies based on intellectual property created within our own research community. We seek strong co-investor syndicates to develop products across a range of categories including drugs, devices, diagnostics, and digital health. Initial investments are directed at the seed and Series A stages, where our participation attracts capital and talent into the most difficult-to-fund phase of company development. When we invest, we expect to support each portfolio company through its entire financing lifecycle.
In addition to providing the necessary venture capital, we leverage our experience in starting and growing companies, our expertise in the medical industry, and our network of scientific and business talent to build great companies.
Competitive advantage of Mass General Brigham
The power of collective impact from our vast research enterprise provides an unrivaled competitive advantage to build next generation life science companies capable of bringing innovative therapeutics to patients in need and delivering outstanding returns to our investors.
Academic medical centers
We source deals from our five research and teaching hospitals, which collectively represent the largest teaching affiliate of Harvard Medical School.
Our founding members
Specialty hospitals
-
Therapeutics
First-in-class therapeutics, including traditional and novel modalities, across indications with significant unmet need.
-
Digital health
Information and communications technology to enable better care delivery.
-
Diagnostics, devices, and tools
Methods, metrics and tools to support research insight and guide clinical decision-making.
Advancing translational science
Our venture capital team leads Mass General Brigham’s translational acceleration platform which includes multiple commercialization programs for advancing projects to the seed stage where they will attract venture capital investment.
These funding sources serve as a powerful substrate to increase the probability of success in some of the most promising areas of medical research. We combine these collective resources with our venture funding and company-building capabilities to enable transformative technologies that are primed for clinical application.
